Luye Pharma Group Ltd. (HKG:2186)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.660
-0.030 (-1.12%)
Apr 29, 2026, 4:08 PM HKT
33.00%
Market Cap 10.75B
Revenue (ttm) 7.02B
Net Income (ttm) 688.55M
Shares Out 3.99B
EPS (ttm) 0.18
PE Ratio 15.22
Forward PE 13.38
Dividend n/a
Ex-Dividend Date n/a
Volume 7,608,000
Average Volume 40,003,228
Open 2.690
Previous Close 2.690
Day's Range 2.650 - 2.690
52-Week Range 1.900 - 4.490
Beta 0.92
RSI 47.64
Earnings Date Mar 30, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg... [Read more]

Sector Healthcare
Founded 1994
Employees 5,115
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2186
Full Company Profile

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.